Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

target="_new">http://www.nasdaq.com.

Fourth Quarter and Year End 2007 Financial Results

-- Net loss for the fourth quarter of 2007 was $8.7 million, or

$0.11 per share, compared with a net loss for the fourth quarter of

2006 of $4.4 million, or $0.07 per share. Net loss for the twelve

months ended December 31, 2007 was $23.9 million, or $0.32 per share,

compared with a net loss of $14.8 million, or $0.24 per share, for

the comparable period last year.

-- Revenues for the fourth quarter of 2007 were $1.3 million, compared

with $426,000 for the fourth quarter of 2006. Cumulase product sales

for the fourth quarter of 2007 were $70,000, compared with $105,000

for the fourth quarter of 2006. Revenues under collaborative

agreements for the fourth quarter of 2007 were $1.2 million, compared

with $311,000 for the fourth quarter of 2006. Revenues under

collaborative agreements in 2007 primarily consisted of the

amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter and

Roche of $652,000.

-- Research and development expenses for the fourth quarter of 2007 were

$7.3 million, compared with $2.7 million for the fourth quarter of

2006, reflecting increased compensation expenses including

share-based compensation expenses, research and development spending

on our various pre-clinical and clinical programs, and manufacturing

costs associated with the manufacturing scale-up of the Company's

rHuPH20 enzyme.

-- Selling, general and administrative expenses for the fourth quarter

of 2007 were $3.9 million, compared with $2.4 million for the fourth

quarter of 2006, reflecting increases in compensation expenses

including
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... 29, 2014  The Society for Clinical Research ... program for the 9 th annual Site ... Amelia Island , Florida.  The focus on ... unchanged, however, the topics and format will allow ... among all stakeholders with a continued focus on ...
(Date:7/29/2014)... July 29, 2014  Discovery Laboratories, Inc. (Nasdaq: ... a new standard of respiratory critical care, will report ... 5, 2014 before the open of the U.S. ... host a live teleconference and webcast at 9:00 a.m. ... call, Discovery Labs, management will discuss the 2014 ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... of VIA, and,James G. Stewart, senior vice president ... at the Seventh Annual Needham & Company,Biotechnology and ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... systems, today announced that President and,Chief Executive Officer Michael ... company,s business outlook, growth strategy and,recent financial results at ... On Thursday, June 12, the company will present at ...
... 3 Masimo Corporation,(Nasdaq: MASI ), the ... announced,that it is scheduled to present at the ... Ritz Carlton, Laguna Nigel, in Dana Point, CA,on ... Joe E. Kiani, Chairman and,CEO, will be presenting., ...
Cached Biology Technology:Cynosure Announces Schedule of Upcoming Investor Conferences 2Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... brain cells suggests that the effects of a commonly ... are temporary. , The study, published in this week,s ... conducted by biologists at the University of California, San ... in response to concerns, arising from multiple studies on ... general anesthetics may increase their susceptibility to long-term cognitive ...
(Date:7/28/2014)... of the top 10 U.S. cities that have seen ... inconveniences as frequent road closures, overwhelmed storm drains and ... new NOAA technical report. , This nuisance flooding, caused ... U.S. coasts, between 300 and 925 percent since the ... Flood Frequency Changes around the United States, also finds ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3
... difference between a lifeless sack of chemicals and ... they're organized, according to Stanford biophysical chemist Steven ... California-Davis and Lawrence Livermore National Laboratory, he has ... unprecedented resolution-on the order of 100 nanometers, a ...
... million grant from the National Cancer Institute, a Wake Forest ... the effectiveness of a drug that he developed for the ... M.D., Ph.D., pioneered a method to destroy cells of glioblastoma ... is currently being tested in clinical trials and Debinski is ...
... plumage, flamingos are a curiosity of nature. Now a new ... anatomical oddity that helps flamingos eat: erectile tissue. , Flamingos ... shallow water, they bend their necks, tilt their bills upside ... Their large tongue acts like a piston, sucking water into ...
Cached Biology News:With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2Ohio University researchers discover evolutionary oddity in flamingos 2
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
Biology Products: